Enteris BioPharma has launched operations for its oral peptide delivery platform, Peptelligence, which is designed to extend the technology to small molecule therapeutics. Enteris recently acquired the Peptelligence platform, along with nasal delivery technology and a recombinant manufacturing process for therapeutic peptides, from Unigene Laboratories.
 
In conjunction with the launch, Enteris has appointed Brian Zietsman as president and chief financial officer, Nozer Mehta, Ph.D., as chief scientific officer, and Paul Shields, Ph.D., as vice president of operations. Mr. Zietsman, Dr. Mehta and Dr. Shields will lead formulation solutions for peptides and small molecules that leverage the company’s delivery platform technologies including Peptelligence.
 
Most recently, Mr. Zietsman, Dr. Mehta and Dr. Shields held executive positions at Unigene Laboratories. Mr. Zietsman was previously chief financial officer. Dr. Mehta held the positions of chief scientific officer and vice president of R&D. Dr. Shields previously served as vice president of Manufacturing Operations, director of Plant Operations, and Plant Manager.
 
Mr. Zietsman said, “I greatly welcome the opportunity to lead Enteris BioPharma as we seek to become the industry leader in the oral delivery of peptides and difficult to deliver small molecule therapeutics. As a company, we are focused on solving challenging formulation issues for our partners using our proprietary Peptelligence technology in combination with our formulation development and manufacturing expertise. In doing so, we are targeting the myriad therapeutic indications in which physician acceptance and patient compliance can be improved through more convenient and effective medications.”